Pular para o conteúdo principal
Ranking Invest

AQST - Aquestive Therapeutics, Inc.

Segmento: HealthcareAquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Análise Ranking Invest

Valor de Mercado
$ 522.13 Mi
IVR
-0.43Índice proprietário de comparação relativa: -0,43.
IVR2
-0.33Leitura proprietária complementar: -33%.
MLL
-0.33Leitura proprietária complementar: -33%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

-$ 56.59 Mi

Dívida Líquida

-$ 43.46 Mi

L4T

-$ 78.23 Mi

MM4T

-146.66%

Indicadores Básicos

ROE

138.24%

Índices de Previsibilidade

Receita Líquida

D0.09

Lucro

E1.13

Margem

E1.12

Índices de Tendência

Receita Líquida

C3.73

Lucro

F-6.26

Margem

F-5.49

Índices de Endividamento

DIV/PAT

0.77

DIV/L4T

0.56

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.